Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy

Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy: Real-World Data in Five Russian Centers

Research output: Contribution to journal › Meeting Abstract › peer-review

Department of Hospital Therapy

Tamara Chitanava
Elza Lomaia
Vasily Shuvaev
Irina Martynkevich
Elizaveta Efremova
Anna Kersilova
Agniia-Polina Poshivay
Elena Koryagina
Natalia Ilyina
Natalia Dorofeeva
Nadezhda Medvedeva
Anna Klimovich
Tatiana Shneider
Svetlana Stepanova
Nadiya Siordiya
Eugenia Sbityakova
Natalia Lazorko
Olga Merzlikina
Natalia Polezhajkovskaya
Darina Zammoeva
Nadezhda Shnalieva
Elena Tochenaya
Andrey Zaritskey

Original language	English
Pages (from-to)	S242-S242
Number of pages	1
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
State	Published - Sep 2020

Research areas

chronic myeloid leukemia, CML, tyrosine kinase inhibitor, TKI, third-line therapy, prognosis

ID: 62256647

SPbU Researchers Portal

Pure is an Elsevier product
This information resource may contain archival materials mentioning individuals
or legal entities included in the register of foreign agents by the Ministry of Justice
of the Russian Federation.
Log in to Pure